Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Flyte (NYSE American: VTAK) said it is accelerating expansion in short‑haul regional markets on April 20, 2026, as major airlines cut routes amid rising jet fuel costs and network redeployment. Flyte operates FAA Part 135 service with Cirrus Vision Jets and reports active, revenue‑generating operations to capture displaced demand.
The company positions point‑to‑point, right‑sized flights as a lower‑fuel, high‑frequency alternative in underserved corridors, notably in the Northeast, where airline service is declining.
Catheter Precision (NYSE: VTAK) completed a shareholder-approved acquisition of Fly Flyte on April 15, 2026, making Flyte a wholly owned operating subsidiary. The deal immediately consolidates 100% of Flyte’s revenue, assets, and operations into VTAK and provides direct exposure to cash flow from FAA Part 135 certified regional air services.
The acquisition gives VTAK control of capital allocation, fleet expansion, and a revenue-generating aviation platform positioned for scalable growth in regional air mobility ahead of eVTOL commercialization.
Catheter Precision (NYSE American: VTAK) announced that a VIVO study has been accepted for publication in EP Europace on April 13, 2026. The 31‑patient study mapped 48 VTs and found ECGi mapping with VIVO accurately predicted arrhythmogenic substrate for scar‑dependent VT and may improve procedural efficiency.
The study reported VIVO localization in NICM patients showed 100% specificity and 66.7% sensitivity for epicardial VTs versus a four‑step ECG algorithm (sensitivity 50%, specificity 0%). The company plans a larger multi‑center study later in 2026.
Catheter Precision (NYSE American: VTAK) will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026. The company said it will use the event to share new data, engage key opinion leaders and educate physicians and distributors about LockeT after CE Mark receipt.
This appearance is the company's first large European conference since LockeT received CE Mark clearance and aims to support expanded product use and commercial momentum.
Catheter Precision (NYSE American: VTAK) announced acceptance of a manuscript in the Journal of Interventional Cardiac Electrophysiology on April 6, 2026. The study of LockeT in 139 patients reported high procedural success, rapid hemostasis, early ambulation, and low complication rates for large-bore venous access closure.
The peer-reviewed acceptance supports LockeT as a feasible venous closure strategy in electrophysiology practice and may aid the company’s commercialization and hospital engagement efforts in the US and Europe.
Catheter Precision (NYSE American: VTAK) engaged a strategic advisor on April 2, 2026 to formally market for sale its cardiac electrophysiology business. The process aims to monetize legacy medical device assets (LockeT and VIVO) that have FDA market clearance and the CE mark, while the company sharpens focus on its Flyte aviation platform. Management says the sale could unlock shareholder value and that monetization would position the company as a pure‑play aviation business through disciplined capital allocation and increased execution and transparency.
Catheter Precision (NYSE American: VTAK) reported full-year 2025 results and described a strategic expansion. Key 2025 metrics: revenue $819 thousand (+95% YoY), gross margin 92.3%, and net loss $17.2 million (including $7.8 million non-cash).
Post-year-end the company acquired Flyte, a revenue-generating regional air mobility operator, and completed financings to strengthen capital for a dual-platform strategy across medical devices and aviation.
Catheter Precision (NYSE American: VTAK) subsidiary Fly Flyte announced expansion of its Vision Jet-powered Hops short‑haul regional platform, operating three aircraft today with two additional Vision Jets under accepted bids and expected to be fully operational by Memorial Day 2026.
The Hops model targets flights under ~500 miles, offering private‑terminal access, rapid booking‑to‑boarding, AI-driven scheduling/pricing, right‑sized economics, and safety features (CAPS, Safe Return) to enable high‑frequency regional travel.
Catheter Precision (NYSE American: VTAK) launched Flyte Hops Florida on March 16, 2026, expanding its Flyte regional aviation network to cover the entire East Coast from Maine to Florida. A soft rollout in Florida produced more than $160,000 of inbound bookings on a single aircraft, supporting plans to operate at least five Cirrus Vision Jets by Memorial Day 2026.
Flyte targets short-haul routes using Cirrus Vision Jets equipped with CAPS parachute technology, focusing on underutilized regional airports and planned expansion into California and Texas later in 2026.
Catheter Precision (NYSE American: VTAK) announced institutional financing commitments of up to $88 million and the completed acquisition of Flyte, positioning the company to scale a national regional aviation platform.
Funds are intended to support fleet expansion, market growth, platform scaling, balance sheet simplification and reduction of legacy liabilities; the transaction is subject to customary closing conditions including shareholder approval.